Follicular Lymphoma

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with relapsed or refractory diffuse large B-cell lymphoma, according to results of a phase 1b/phase 2 trial.

SAN DIEGO — The addition of tafasitamab-cxix to lenalidomide and rituximab reduced risk for progression, relapse or death by more than 50% for patients with relapsed or refractory follicular lymphoma, according to study results.

Three women oncologist researchers at Dana Farber Cancer Institute have been named recipients of the Damon Runyon Cancer Research Foundation Clinical Investigator Award.

The addition of tafasitamab-cxix to lenalidomide and rituximab improved outcomes for patients with relapsed or refractory follicular lymphoma, according to the agent’s manufacturer.

The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adults with relapsed or refractory follicular lymphoma who have received two or more previous lines of therapy.

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of adults with relapsed or refractory follicular lymphoma who received at least two prior lines of systemic therapy.

The FDA granted accelerated approval to zanubrutinib in combination with obinutuzumab for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, according to a press release.

SAN DIEGO — Limited duration loncastuximab tesirine in addition to rituximab appeared well tolerated and highly effective for relapsed or refractory follicular lymphoma, according to data presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with newly diagnosed high-burden follicular lymphoma, according to researchers.

Bayer will work with the FDA toward voluntary withdrawal of its follicular lymphoma treatment copanlisib from the U.S. market, according to a company-issued press release.